Metabolic Syndrome (MS) is defined as a constellation of cardiometabolic risk factors that are associated with an increased risk of Cardiovascular Disease (CVD) and type 2 diabetes (T2D). T2D and CVD affect increasing number of young and social active people, so that the prevention of these diseases is a strategical aim of health systems all over the world, the main part of which is treatment of the MS. There is no a definitive therapy of the MS unless reduction of the cardiometabolic risk factors as visceral obesity, dyslipidaemia, arterial hypertension and hyperglycaemia. Even in individuals with genetic predisposition for development of T2D, the environmental factors like diet and physical activity could influence the development of diabetes. Consequently, the change in lifestyle aimed to a reduction of body weight is the first and most important step for diabetic prevention. In individuals who do not get the desirable result, the addition of medical treatment is a helpfull alternative.
Citation: Kamenova P, Atanasova I, Kirilov G (2014) Metformin Reduces Cardiometabolic Risk Factors in People at High Risk for Development of Type 2 Diabetes and Cardiovascular Disease. J Diabetes Metab 5:470. doi: 10.4172/2155-6156.1000470